Loading organizations...
§ Private Profile · Amsterdam, Netherlands
Molecular diagnostics company developing genomic tests to predict breast cancer recurrence and guide personalized treatment decisions.
Agendia is a precision oncology and molecular diagnostics company that develops genomic testing solutions for breast cancer, operating from its dual headquarters in Amsterdam, Netherlands, and Irvine, California. The organization generates revenue by providing proprietary genomic profiling tests, such as MammaPrint and BluePrint, which analyze tumor biology to assist physicians in determining personalized treatment plans for oncology patients globally. Operating with an estimated workforce of 200 to 500 employees, the enterprise has secured over $200 million in total venture and debt funding to support its clinical research and laboratory services. The company has established strategic partnerships with entities like Illumina and the Netherlands Cancer Institute, while receiving financial backing from lead investors including Athyrium Capital Management, Korys, and ING Corporate Investments. Agendia was founded in 2003 by René Bernards and Laura van 't Veer.
Agendia has raised $177.9M across 5 funding rounds.
Agendia has raised $177.9M in total across 5 funding rounds.
Agendia has raised $177.9M across 5 funding rounds. Most recently, it raised $35.0M Other Equity in July 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 25, 2018 | $35M Venture Round | Athyrium Capital Management | — | Announced |
| Mar 14, 2014 | $20.9M Debt Financing | Peter Stein | — | Announced |
| May 31, 2012 | $65M Venture Round | Debiopharm | Breedinvest, ING Corporate Investments, Korys, VAN Herk Ventures | Announced |
| Sep 1, 2009 | $23M Series E | — | Forbion | Announced |
| Aug 1, 2007 | $34M Series D | — | Forbion | Announced |
Agendia has raised $177.9M in total across 5 funding rounds.
Agendia's investors include Athyrium Capital Management, Peter Stein, Debiopharm, Breedinvest, ING Corporate Investments, Korys, Van Herk Ventures, Forbion.
Agendia is a privately held precision oncology company specializing in genomic diagnostic tests for early-stage breast cancer, offering products like MammaPrint® and BluePrint® to provide biology-based insights for personalized treatment decisions.[1][2][3] These assays analyze tumor biology to assess recurrence risk and molecular subtyping, helping physicians minimize under- and over-treatment for patients regardless of age, race, or ethnicity, with results delivered in 6 days from a single sample.[2][4][7] Headquartered in Amsterdam with a lab in Irvine, CA, Agendia serves oncologists, patients, and care teams globally, focusing on early intervention while expanding into recurrence monitoring and metastatic tools, backed by studies like the FLEX database—the world's largest whole-transcriptome real-world evidence breast cancer dataset.[2][3][5]
The company demonstrates strong growth momentum through 2024 achievements, including global expansion (Europe, Asia, Latin America via NGS decentralized testing), clinical adoption, market access gains, and partnerships with institutions and advocacy groups.[1][2] Named 2025 "Best Overall Genomics Company" by MedTech Breakthrough, Agendia continues advancing its pipeline with cutting-edge NGS and microarray technologies.[4]
Agendia was founded in 2003 in Amsterdam as Amsterdam Genomics Diagnostics by world-renowned researchers from the Netherlands Cancer Institute, driven by a desire to predict cancer metastasis more accurately than traditional clinical factors like age or tumor grade.[1][2][3] This marked a shift toward genomic profiling of the complete human genome for unbiased gene selection in breast cancer diagnostics.[1][3] Early traction came from developing MammaPrint® (breast cancer risk-of-recurrence test) and BluePrint® (molecular subtyping test) on microarray technology, establishing Agendia as a leader in precision oncology.[1][6]
Pivotal moments include launching NGS-based MammaPrint + BluePrint kits for decentralized testing in Europe and Asia, creating a Center of Innovation and R&D Excellence in Amsterdam, and building the FLEX Study for real-world evidence.[1][2][3] Led by CEO Mark R. Straley, the company evolved from a Dutch research spinout to a global player with state-of-the-art labs in Irvine, CA, committed to patient-first innovation.[1][2][5]
Agendia rides the precision oncology trend, leveraging genomic sequencing (microarray to NGS) to shift breast cancer care from one-size-fits-all to biology-driven personalization, addressing overtreatment in early-stage cases.[1][3][4] Timing aligns with rising demand for real-world evidence databases like FLEX, which aggregate whole-transcriptome data to refine treatments amid advancing therapies (e.g., targeted hormone options).[2][5] Market forces favoring Agendia include global NGS adoption, decentralized testing reducing logistics barriers in Europe/Asia, and regulatory expansions enabling wider access.[1][2]
By influencing standards through studies and partnerships, Agendia shapes the ecosystem: empowering clinicians with actionable insights, improving outcomes/quality of life, and paving the way for lifecycle-spanning tools in breast cancer management.[3][5][7]
Agendia is poised for accelerated growth in 2025 via NGS global rollout, FLEX Study expansions, and pipeline advancements in recurrence/metastatic testing, building on 2024's clinical, partnership, and market wins.[2][5] Trends like AI-integrated genomics, real-world data proliferation, and immunotherapy synergies will amplify its impact, potentially redefining breast cancer standards worldwide.[3][4] As precision oncology matures, Agendia's patient-centric biology insights—rooted in its 2003 genomic foresight—will evolve from early diagnostics to full treatment lifecycle influence, sustaining its leadership in minimizing disease burdens.[1][3]